Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
October 11, 2023 08:00 ET
|
Vir Biotechnology, Inc.
Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
July 20, 2023 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 11, 2022 16:03 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head...